Quitkin F, Rifkin A, Klein D F
Arch Gen Psychiatry. 1979 Jul;36(7):749-60. doi: 10.1001/archpsyc.1979.01780070027003.
Data from double-blind, placebo-controlled trials of the monoamine oxidase (MAO) inhibitors show that phenelzine is clearly effective in neurotic or atypical depressives, but the findings concerning its effect in endogenous depressives are inconclusive. Although few controlled studies have been done with tranylcypromine, similar conclusions are warranted. Studies have contrasted MAO inhibitors and tricyclic antidepressants (TCAs) to gain further information about the type of patients likely to respond to MAO inhibitors. We believe that simply contrasting the relative efficacy of TCAs and MAO inhibitors is outdated. Neurotic or atypical depression is probably a heterogeneous syndrome, and delineation of subtypes responsive to specific antidepressants is needed. The implications of fast acetylation, selective MAO inhibitors, types MAOA and MAOB, and measures of platelet MAO inhibition are discussed in this article.
单胺氧化酶(MAO)抑制剂的双盲、安慰剂对照试验数据表明,苯乙肼对神经症性或非典型抑郁症患者显然有效,但关于其对内源性抑郁症患者疗效的研究结果尚无定论。虽然针对反苯环丙胺的对照研究较少,但也可得出类似结论。已有研究对MAO抑制剂和三环类抗抑郁药(TCA)进行了对比,以获取更多关于可能对MAO抑制剂有反应的患者类型的信息。我们认为,单纯对比TCA和MAO抑制剂的相对疗效已过时。神经症性或非典型抑郁症可能是一种异质性综合征,需要明确对特定抗抑郁药有反应的亚型。本文讨论了快速乙酰化、选择性MAO抑制剂、MAOA和MAOB型以及血小板MAO抑制测量的意义。